Mendus

.Hero-module--bg-image--629a6:before { opacity: 1; background-image: url('/static/64a4b5993a28d020b3cc5551b430f90f/985d0/start-page-2025Q2-1-scaled-e1755757848694.jpg'); }

Changing the course of cancer treatmentWe explore the power of the immune system to improve long-term survival of cancer patients, while preserving health and quality of life.
About us
Press release
<picture><source type="image/webp" srcSet="/static/b87cea890a9f450686f1b7a0a683c311/d4352/ASCO-2025-1-e1748851502935.webp 623w,/static/b87cea890a9f450686f1b7a0a683c311/6b582/ASCO-2025-1-e1748851502935.webp 1245w,/static/b87cea890a9f450686f1b7a0a683c311/c6928/ASCO-2025-1-e1748851502935.webp 2490w" sizes="(min-width: 2490px) 2490px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 2490px) 2490px, 100vw" decoding="async" loading="lazy" src="/static/b87cea890a9f450686f1b7a0a683c311/2ecea/ASCO-2025-1-e1748851502935.png" srcSet="/static/b87cea890a9f450686f1b7a0a683c311/000ff/ASCO-2025-1-e1748851502935.png 623w,/static/b87cea890a9f450686f1b7a0a683c311/98bce/ASCO-2025-1-e1748851502935.png 1245w,/static/b87cea890a9f450686f1b7a0a683c311/2ecea/ASCO-2025-1-e1748851502935.png 2490w" alt=""/></picture>
Mendus presents at ASCO 2025More details 
<picture><source type="image/webp" srcSet="/static/48407146a7282fec8f811ea39c36c80e/5cf40/251002--e1759385142797.webp 147w,/static/48407146a7282fec8f811ea39c36c80e/1bee1/251002--e1759385142797.webp 294w,/static/48407146a7282fec8f811ea39c36c80e/b7b1b/251002--e1759385142797.webp 588w" sizes="(min-width: 588px) 588px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 588px) 588px, 100vw" decoding="async" loading="lazy" src="/static/48407146a7282fec8f811ea39c36c80e/c5078/251002--e1759385142797.png" srcSet="/static/48407146a7282fec8f811ea39c36c80e/df79c/251002--e1759385142797.png 147w,/static/48407146a7282fec8f811ea39c36c80e/cf5d1/251002--e1759385142797.png 294w,/static/48407146a7282fec8f811ea39c36c80e/c5078/251002--e1759385142797.png 588w" alt=""/></picture>
Press Release More details
<picture><source type="image/webp" srcSet="/static/6f596d0819080c4d8a19c1b047f56ecf/c9fa3/interview-CMO-e1758277379668.webp 111w,/static/6f596d0819080c4d8a19c1b047f56ecf/3b9e7/interview-CMO-e1758277379668.webp 223w,/static/6f596d0819080c4d8a19c1b047f56ecf/4c674/interview-CMO-e1758277379668.webp 445w" sizes="(min-width: 445px) 445px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 445px) 445px, 100vw" decoding="async" loading="lazy" src="/static/6f596d0819080c4d8a19c1b047f56ecf/35415/interview-CMO-e1758277379668.png" srcSet="/static/6f596d0819080c4d8a19c1b047f56ecf/0e3e1/interview-CMO-e1758277379668.png 111w,/static/6f596d0819080c4d8a19c1b047f56ecf/c2bdf/interview-CMO-e1758277379668.png 223w,/static/6f596d0819080c4d8a19c1b047f56ecf/35415/interview-CMO-e1758277379668.png 445w" alt=""/></picture>
Spotlight from Q2 2025 report: Interview with  Tariq MughalRead the full interview
CEO comment
<picture><source type="image/webp" srcSet="/static/292a97e4402d8b7973a59f062391483f/f0111/Manting_banner_headspace-scaled-e1746523332415.webp 428w,/static/292a97e4402d8b7973a59f062391483f/6e776/Manting_banner_headspace-scaled-e1746523332415.webp 855w,/static/292a97e4402d8b7973a59f062391483f/bd09f/Manting_banner_headspace-scaled-e1746523332415.webp 1710w" sizes="(min-width: 1710px) 1710px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 1710px) 1710px, 100vw" decoding="async" loading="lazy" src="/static/292a97e4402d8b7973a59f062391483f/a1257/Manting_banner_headspace-scaled-e1746523332415.jpg" srcSet="/static/292a97e4402d8b7973a59f062391483f/11168/Manting_banner_headspace-scaled-e1746523332415.jpg 428w,/static/292a97e4402d8b7973a59f062391483f/e5cca/Manting_banner_headspace-scaled-e1746523332415.jpg 855w,/static/292a97e4402d8b7973a59f062391483f/a1257/Manting_banner_headspace-scaled-e1746523332415.jpg 1710w" alt=""/></picture>
Expanding the vididencel opportunityMore details 
Press Release
<picture><source type="image/webp" srcSet="/static/e5ee97787b6c10b6d5345d23a5784ed5/ca9c4/250723-USPTO-e-e1753256265459.webp 619w,/static/e5ee97787b6c10b6d5345d23a5784ed5/a55b4/250723-USPTO-e-e1753256265459.webp 1238w,/static/e5ee97787b6c10b6d5345d23a5784ed5/d45d5/250723-USPTO-e-e1753256265459.webp 2475w" sizes="(min-width: 2475px) 2475px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 2475px) 2475px, 100vw" decoding="async" loading="lazy" src="/static/e5ee97787b6c10b6d5345d23a5784ed5/64122/250723-USPTO-e-e1753256265459.png" srcSet="/static/e5ee97787b6c10b6d5345d23a5784ed5/76a15/250723-USPTO-e-e1753256265459.png 619w,/static/e5ee97787b6c10b6d5345d23a5784ed5/23e78/250723-USPTO-e-e1753256265459.png 1238w,/static/e5ee97787b6c10b6d5345d23a5784ed5/64122/250723-USPTO-e-e1753256265459.png 2475w" alt=""/></picture>
Vididencel Granted US Patent for Use in Ovarian Cancer  More details 
Press release
<picture><source type="image/webp" srcSet="/static/b87cea890a9f450686f1b7a0a683c311/d4352/ASCO-2025-1-e1748851502935.webp 623w,/static/b87cea890a9f450686f1b7a0a683c311/6b582/ASCO-2025-1-e1748851502935.webp 1245w,/static/b87cea890a9f450686f1b7a0a683c311/c6928/ASCO-2025-1-e1748851502935.webp 2490w" sizes="(min-width: 2490px) 2490px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 2490px) 2490px, 100vw" decoding="async" loading="lazy" src="/static/b87cea890a9f450686f1b7a0a683c311/2ecea/ASCO-2025-1-e1748851502935.png" srcSet="/static/b87cea890a9f450686f1b7a0a683c311/000ff/ASCO-2025-1-e1748851502935.png 623w,/static/b87cea890a9f450686f1b7a0a683c311/98bce/ASCO-2025-1-e1748851502935.png 1245w,/static/b87cea890a9f450686f1b7a0a683c311/2ecea/ASCO-2025-1-e1748851502935.png 2490w" alt=""/></picture>
Mendus presents at ASCO 2025More details 
<picture><source type="image/webp" srcSet="/static/48407146a7282fec8f811ea39c36c80e/5cf40/251002--e1759385142797.webp 147w,/static/48407146a7282fec8f811ea39c36c80e/1bee1/251002--e1759385142797.webp 294w,/static/48407146a7282fec8f811ea39c36c80e/b7b1b/251002--e1759385142797.webp 588w" sizes="(min-width: 588px) 588px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 588px) 588px, 100vw" decoding="async" loading="lazy" src="/static/48407146a7282fec8f811ea39c36c80e/c5078/251002--e1759385142797.png" srcSet="/static/48407146a7282fec8f811ea39c36c80e/df79c/251002--e1759385142797.png 147w,/static/48407146a7282fec8f811ea39c36c80e/cf5d1/251002--e1759385142797.png 294w,/static/48407146a7282fec8f811ea39c36c80e/c5078/251002--e1759385142797.png 588w" alt=""/></picture>
Press Release More details

<picture><source type="image/webp" srcSet="/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/d7070/Startpage_1-NEW-1.webp 240w,/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/4ce17/Startpage_1-NEW-1.webp 480w,/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/95cd0/Startpage_1-NEW-1.webp 960w" sizes="(min-width: 960px) 960px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 960px) 960px, 100vw" decoding="async" loading="lazy" src="/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/49439/Startpage_1-NEW-1.jpg" srcSet="/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/ff13b/Startpage_1-NEW-1.jpg 240w,/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/28e6b/Startpage_1-NEW-1.jpg 480w,/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/49439/Startpage_1-NEW-1.jpg 960w" alt=""/></picture>
Gaining the 
upper handToday, tumor recurrence is the main cause of cancer-related deaths. We aim to reduce tumor recurrence by harnessing the immune system to act against residual cancer cells.
What we do

<picture><source type="image/webp" srcSet="/static/bfd9bafcd3660b03f3b72edb150264f7/ecbb3/Startpage_2.webp 450w,/static/bfd9bafcd3660b03f3b72edb150264f7/10d3d/Startpage_2.webp 900w,/static/bfd9bafcd3660b03f3b72edb150264f7/7d31d/Startpage_2.webp 1800w" sizes="(min-width: 1800px) 1800px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 1800px) 1800px, 100vw" decoding="async" loading="lazy" src="/static/bfd9bafcd3660b03f3b72edb150264f7/b37a5/Startpage_2.jpg" srcSet="/static/bfd9bafcd3660b03f3b72edb150264f7/ea40c/Startpage_2.jpg 450w,/static/bfd9bafcd3660b03f3b72edb150264f7/a3b1e/Startpage_2.jpg 900w,/static/bfd9bafcd3660b03f3b72edb150264f7/b37a5/Startpage_2.jpg 1800w" alt="&lt;p&gt;Two chemistry laboratory researchers, a young man and a young woman working together in a biology, chemistry research laboratory.= in a university. Focus on the laboratory equipment with the personnel in the background. Photographed in horizontal format.&lt;/p&gt;
"/></picture>
New ways to make a differenceWe apply our understanding of dendritic cell biology to design cancer immunotherapies that stimulate active immunity, the only long-lasting form of immunity.
About us

<picture><source type="image/webp" srcSet="/static/0237bef387e76cffaa6681d16a2b59c4/8cdf4/Startpage_3.webp 302w,/static/0237bef387e76cffaa6681d16a2b59c4/39272/Startpage_3.webp 603w,/static/0237bef387e76cffaa6681d16a2b59c4/0d01b/Startpage_3.webp 1206w" sizes="(min-width: 1206px) 1206px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 1206px) 1206px, 100vw" decoding="async" loading="lazy" src="/static/0237bef387e76cffaa6681d16a2b59c4/e579d/Startpage_3.jpg" srcSet="/static/0237bef387e76cffaa6681d16a2b59c4/8f82e/Startpage_3.jpg 302w,/static/0237bef387e76cffaa6681d16a2b59c4/d2caf/Startpage_3.jpg 603w,/static/0237bef387e76cffaa6681d16a2b59c4/e579d/Startpage_3.jpg 1206w" alt="&lt;p&gt;Molecular Structure. Science background. 3D Render&lt;/p&gt;
"/></picture>
Invest in future cancer careMendus is listed on NASDAQ Stockholm under the ticker symbol IMMU. You will find all relevant information on the Mendus share in our Investors section.
Investors

Latest newsNews and Events
No articles found

.FullWidthImage-module--bg-image-mobile--ba5fc.FullWidthImage-module--hide-in-mobile--9cd89:before { opacity: 1; background-image: url('/static/58920a993c01776af52e6d8a69a7452d/60e72/What-we-do_1-mobile-1.jpg'); }

What we do

Changing the course of cancer treatment

Mendus presents at ASCO 2025

Press Release

Spotlight from Q2 2025 report: Interview with Tariq Mughal

Expanding the vididencel opportunity

Vididencel Granted US Patent for Use in Ovarian Cancer

Mendus presents at ASCO 2025

Press Release

Gaining the upper hand

New ways to make a difference

Invest in future cancer care

Latest news

What we do

Gaining the
upper hand